A recent study published in May 2024 unveiled a long-term outcome of Semaglutide, known as Wegovy or Ozempic. This builds on the SELECT trial, which showed Wegovy could reduce major cardiovascular events by 20% in individuals with obesity and no diabetes. Conducted by Ryan et al., the study followed participants for 208 weeks, or about four years.
Try My New Calorie Calculator!
Calculate your daily calorie and protein targets to help you achieve your weight goals.